Market cap $459.47B
Enterprise value $371.40B
Revenue $81.796B
EBITDA $28.853B
Income $38.476B
Revenue Q/Q -13.59%
Revenue Y/Y -15.03%
P/E 9.54
Forward P/E 13.89
EV/Sales 4.54
EV/EBITDA 12.87
EV/EBIT 8.83
PEG 3.79
Price/Sales 5.62
P/FCF 24.57
Price/Book 6.68
Book/Share 21.80
Cash/Share 7.27
FCF yield 4.07%
Employees 152,700
RPE $535.665k
Volume 6.035M / 7.022M
Relative vol. 0.86 ×
EPS 15.26
EPS Q/Q -1.92%
Est. EPS Q/Q 4.69%
Profit margin 41.28%
Oper. margin 25.24%
Gross margin 68.82%
EBIT margin 51.41%
EBITDA margin 35.27%
Ret. on assets 22.07%
Ret. on equity 53.97%
ROIC 21.22%
ROCE 34.12%
Volatility 1.42%
Beta 0.22
RSI 41.96
Range $145.27 – $146.39
52 weeks $143.13 – $175.97
SMA 50 $149 -2.06%
SMA 200 $155 -6.11%
1 year target $167 +14.35%
Mean Recomm. 1.78
Shares outst. 2.407B
Shares float 0.000 0.00%
Short % of float 0.49%
Short ratio 1.94

Recent Johnson & Johnson news

Tuesday, 18 June 2024
 
reuters
J&J hit with new class action over talc seeking medical monitoring for cancer
Thursday, 6 June 2024
 
investingchannel
Is Johnson & Johnson the Best Mega-Cap Dividend Aristocrat Stock?
Friday, 31 May 2024
 
msn
The Best Place in Oklahoma for a Couple to Live on Only Social Security
insidermonkey
The Most Profitable Biotechnology Company in the World
Wednesday, 29 May 2024
 
duckduckgo
Sarepta Therapeutics Set to Join S&P MidCap 400
benzinga
Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial
Tuesday, 28 May 2024
 
businesswire
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Wednesday, 22 May 2024
 
msn
Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company?
reuters
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies
Monday, 20 May 2024
 
gurufocus
Johnson & Johnson's Dividend Analysis
Tuesday, 14 May 2024
 
insidermonkey
Is Ardagh Metal Packaging SA the Best High-Dividend Penny Stock to Buy Now?
Monday, 13 May 2024
 
news.bloomberglaw
Asian Stocks Set for Cautious Open as CPI Looms: Markets Wrap
yahoo
Johnson & Johnson to sell remaining stake in Kenvue
Wednesday, 8 May 2024
 
msn
10 Future Dividend Kings in the Next 5 Years or Less
Tuesday, 7 May 2024
 
msn
15 Best S&P 500 Dividend Stocks To Buy Now
Monday, 6 May 2024
 
benzinga
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
insidermonkey
10 Best May Dividend Stocks To Buy
Friday, 3 May 2024
 
insidermonkey
30 Most Profitable Companies with Highest Margins in the World
investors
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
Wednesday, 1 May 2024
 
apnews
J&J subsidiary proposes paying about $6.48B over 25 years to settle talc lawsuits
reuters
J&J advances $6.475 billion settlement of talc cancer lawsuits
Monday, 29 April 2024
 
reuters
J&J, Bristol Myers lose challenges to US drug price negotiation program
biospace
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Sunday, 28 April 2024
 
insidermonkey
Dividend Stock Portfolio For Income: Top 15 Stocks
Saturday, 27 April 2024
 
insidermonkey
10 Best Long Term Low Risk Stocks to Buy
Wednesday, 24 April 2024
 
insidermonkey
14 Dividend Growth Stocks with Highest Growth Rates
Monday, 22 April 2024
 
insidermonkey
10 Best Performing Biotech ETFs in 2024
Sunday, 21 April 2024
 
insidermonkey
10 Stocks American Politicians are Buying in 2024
insidermonkey
10 Best Soaps and Cleaning Materials Stocks to Buy
Friday, 19 April 2024
 
duckduckgo
Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert
insidermonkey
12 Best Diversified Stocks To Invest In
insidermonkey
Top 12 Ultra-High Yield Dividend Stocks to Buy
Thursday, 18 April 2024
 
yahoo
US FDA mandates label updates on CAR-T cancer therapies
reuters
J&J wins trial over Florida woman who claimed its baby powder caused her cancer
insidermonkey
14 Best Large Cap Dividend Growth Stocks To Buy Now
Tuesday, 16 April 2024
 
yahoo
US STOCKS-Wall Street stocks mixed on higher Treasury yields, rate expectations
reuters
J&J beats first-quarter profit estimates on cancer drugs strength
Monday, 15 April 2024
 
reuters
WHO warns of falsified cough syrup ingredients seized in Pakistan
reuters
UPDATE 1-Tanzania, Rwanda join African recall of J&J children's cough syrup
reuters
Rwanda joins other African countries in recalling J&J children's cough syrup
Saturday, 13 April 2024
 
reuters
South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity
Wednesday, 10 April 2024
 
benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
reuters
Nigeria recalls J&J children's cough syrup over toxic substance
Friday, 5 April 2024
 
barrons
Johnson & Johnson to Buy Shockwave Medical for $13.1 Billion. It’s a Cardio Health Play.
investors
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
Monday, 1 April 2024
 
reuters
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Friday, 29 March 2024
 
insidermonkey
25 Things Every Dividend Investor Should Know
Thursday, 28 March 2024
 
insidermonkey
20 Best Stocks to Buy Right Now According to Financial Media
Tuesday, 26 March 2024
 
reuters
J&J in talks to buy Shockwave Medical, WSJ reports
insidermonkey
25 Countries with the Highest Death Rate From Malnutrition
yahoo
25 Countries with Lowest Rates of Infant Mortality
Monday, 25 March 2024
 
insidermonkey
31 European Countries That Offer Citizenship by Descent
Sunday, 24 March 2024
 
insidermonkey
14 Best Medical Device Stocks To Buy Now
Friday, 22 March 2024
 
insidermonkey
19 Most Densely Populated States in the US
Wednesday, 20 March 2024
 
insidermonkey
20 High Quality Best Foot Creams for Cracked Heels
Tuesday, 19 March 2024
 
insidermonkey
11 Best Dividend ETFs To Buy
Friday, 15 March 2024
 
reuters
UPDATE 1-US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
barrons
Small Investors Could Have Made $5,000 on Cummins Exchange for Atmus Stock
Thursday, 14 March 2024
 
insidermonkey
20 States With the Healthiest Populations
insidermonkey
20 Countries With the Best Healthcare in 2024
gurufocus
Insider Sell: EVP, Global Corp Affairs Vanessa Broadhurst Sells 8,891 Shares of Johnson & ...
Tuesday, 12 March 2024
 
insidermonkey
15 Best States To Live In: 2024 Rankings
insidermonkey
15 Best Retirement Stocks to Buy According to the Media
8-K 20 May 2024 Other Events; Financial Statements and Exhibits
8-K 17 May 2024 Other Events
FWP 14 May 2024 Free Writing Prospectus
FWP 14 May 2024 Free Writing Prospectus
10-Q 1 May 2024 Quarterly report
8-K 1 May 2024 Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits
8-K 29 Apr 2024 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Submission of Matters to a Vote o...
8-K 16 Apr 2024 Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits
10-K 16 Feb 2024 Yearly report
8-K 23 Jan 2024 Results of Operations and Financial Condition; Financial Statements and Exhibits
8-K 5 Dec 2023 Other Events
Insider
Trans.
Transaction
Price per share Total value
John C Reed EVP, Innovative Medicine, R, and D Option 1 May 2024 $151.18 $3,364,511
Vanessa Broadhurst EVP and Global Corp Affairs Sale 13 Mar 2024 $162.16 $1,441,765
Kathryn E Wengel EVP, Chief TO, and Risk Officer Option 13 Feb 2024 $156.47 $101,862
Joseph J Wolk Exec VP and CFO Option 13 Feb 2024 $156.47 $278,517
Jennifer L Taubert EVP and WWC. Innovative Medicine Option 13 Feb 2024 $156.47 $203,724
James D. Swanson EVP and CIO Option 13 Feb 2024 $156.47 $69,942
Timothy Schmid EVP, WW Chair, and MedTech Option 13 Feb 2024 $156.47 $78,079
William Hait EVP, Chief EI, and Med Officer Option 13 Feb 2024 $156.47 $130,496
Elizabeth Forminard Executive VP and General Counsel Option 13 Feb 2024 $156.47 $101,862
Peter Fasolo Exec VP and Chief HR Officer Option 13 Feb 2024 $156.47 $144,735
Joaquin Duato CEO and Chairman of the Board Option 13 Feb 2024 $156.47 $542,951
Q2 2022
19 July 2022
Q2 2022 Earnings Call Transcript
Q1 2022
19 April 2022
Q1 2022 Earnings Call Transcript
Q4 2021
25 January 2022
Q4 2021 Earnings Call Transcript
Q3 2021
19 October 2021
Q3 2021 Earnings Call Transcript
Q2 2021
21 July 2021
Q2 2021 Earnings Call Transcript
Q1 2021
20 April 2021
Q1 2021 Earnings Call Transcript
Q4 2020
26 January 2021
Q4 2020 Earnings Call Transcript
Q3 2020
13 October 2020
Q3 2020 Earnings Call Transcript
Q2 2020
16 July 2020
Q2 2020 Earnings Call Transcript
Q1 2020
14 April 2020
Q1 2020 Earnings Call Transcript
Q4 2019
22 January 2020
Q4 2019 Earnings Call Transcript

82,377 people own Johnson & Johnson on Robinhood

Powered by Robintrack.

Overall analyst rating

Price target

Current $145.65
Average $166.55
Low $139 High $180

Dividends

Ex-dividend date N/A Frequency Quarterly Annual dividend +5.62%
Next dividend N/A Dividend yield 3.30% Growth period 53 years
Last dividend date Yield 3 years 2.94% Growth 3 years +5.70%
Last dividend Yield 5 years 2.76% Growth 5 years +5.83%

Johnson & Johnson dividend history

Johnson & Johnson executives

Insider Age Since Compensation
Alex Gorsky (59) Chairman of the Board and Chief Executive Officer since 2012 59 2012 $25,365,800
Paulus Stoffels (58) Vice Chairman- Executive Committee and Chief Scientific Officer since 2018 58 2018 $14,067,800
Joaquin Duato (57) Vice Chairman - Executive Committee since 2018 57 2018 $13,419,300
Joseph Wolk (53) Chief Financial Officer and Executive Vice President since 2018 53 2018 $7,497,690
Jennifer Taubert (56) Executive Vice President - Worldwide Chairman and Pharmaceuticals since 2018 56 2018 $7,097,300
Michael Ullmann (61) Executive Vice President and General Counsel since 2016 61 2016 $5,336,150
Alex Gorsky (61) Exec. Chairman 61 $4,999,325
Peter Fasolo (57) Chief Human Resource Officer and Executive Vice President since 2016 57 2016 $3,621,280
Dr. Paulus A. Stoffels M.D., Ph.D. (58) Chief Scientific Officer 58 $3,361,844
Joaquin Duato (58) CEO and Director 58 $2,887,910
Joseph J. Wolk CPA (54) Exec. VP and CFO 54 $2,577,183
Joseph J. Wolk C.P.A. (54) Exec. VP and CFO 54 $1,976,200
Jennifer L. Taubert (57) Exec. VP and Worldwide Chairman of Pharmaceuticals 57 $1,921,544
Anne Mulcahy (67) Lead Independent Director since 2012 67 2012 $359,979
Charles Prince (70) Independent Director since 2006 70 2006 $344,979
Mary Beckerle (65) Independent Director since 2015 65 2015 $344,979
Ronald Williams (70) Independent Director since 2011 70 2011 $334,979
D. Scott Davis (68) Independent Director since 2014 68 2014 $329,979
A. Eugene Washington (69) Independent Director since 2012 69 2012 $324,979
Jennifer Doudna (56) Independent Director since 2018 56 2018 $324,979
Mark McClellan (56) Independent Director since 2013 56 2013 $304,979
Ian Davis (69) Independent Director since 2010 69 2010 $304,979
Marillyn Hewson (66) Independent Director since 2019 66 2019 $80,520
Mark Weinberger (58) Independent Director since 2019 58 2019 $8,877
Hubert Joly (60) Independent Director since 2019 60 2019 $8,877
Christopher DelOrefice 2019
Kathryn Wengel (54) Executive Vice President and Chief Global Supply Chain Officer since 2018 54 2018
Michael Sneed (60) Executive Vice President - Global Corporate Affairs and Chief Communication Officer since 2018 60 2018
Thibaut Mongon (50) Executive Vice President, Worldwide Chairman, and Consumer since 2018 50 2018
Ashley McEvoy (49) Executive Vice President - Worldwide Chairman and Medical Devices since 2018 49 2018
Dr. Guy J. Lebeau M.D.
Dr. Peter M. Fasolo Ph.D. (58) Exec. VP and Chief HR Officer 58
Michael H. Ullmann (62) Exec. VP and Gen. Counsel 62
Jessica Moore
Ashley Watson (51) Chief Compliance Officer 51
James Swanson
Robert J. Decker Jr. (49) Controller and Chief Accounting Officer 49
Company Market cap P/E EV/EBITDA P/S P/B P/FCF Change
$459.47B 9.54 12.87 5.62 6.68 24.57 -0.21%
$343.00B 130.71 60.95 9.55 31.84 N/A +0.73%
$291.64B N/A 29.58 5.29 3.28 57.12 +1.59%
$276.92B 140.11 41.01 4.51 7.37 25.08 +0.38%
$203.64B 20.54 12.01 4.36 4.36 17.40 +0.01%
$190.11B 32.20 22.53 4.71 4.90 38.62 +0.52%
$112.22B 157.88 8.87 4.09 4.91 14.20 -1.74%
$104.80B 25.38 16.58 3.24 2.04 21.25 -0.25%
$92.42B 39.40 28.59 4.41 4.97 32.34 +1.15%
$72.52B 17.43 9.77 2.30 4.26 8.59 +0.71%

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

  • Health Care > Pharmaceuticals
  • Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick 08933, United States
  • 732 524 0400
  • Investor relations

Dividends

Ex-dividend date N/A Frequency Quarterly Annual dividend +5.62%
Next dividend N/A Dividend yield 3.30% Growth period 53 years
Last dividend date Yield 3 years 2.94% Growth 3 years +5.70%
Last dividend Yield 5 years 2.76% Growth 5 years +5.83%

Johnson & Johnson dividend history

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

(in millions USD) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Current assets
Cash $25,473 $21,859 $19,728 $21,183
Short term investments $745 $1,068 $3,783 $7,322
Net receivables $14,946 $14,873 $14,798 $16,777
Inventory $11,383 $11,181 $11,198 $12,888
Total current assets $57,002 $53,495 $53,703 $60,567
Long term investments
Property, plant & equipment $19,632 $19,898 $18,821 $20,576
Goodwill & intangible assets $70,902 $70,733 $71,145 $91,686
Total noncurrent assets $114,964 $114,063 $112,358 $131,119
Total investments $745 $1,068 $3,783 $7,322
Total assets $171,966 $167,558 $166,061 $191,686
Current liabilities
Accounts payable $8,174 $9,632 $8,355 $10,443
Deferred revenue
Short long term debt $8,550 $3,451 $3,870 $11,701
Total current liabilities $48,725 $46,282 $44,370 $54,170
Long term debt $25,082 $25,881 $26,051 $33,901
Total noncurrent liabilities $53,221 $52,502 $50,463 $61,107
Total debt $33,632 $29,332 $29,921 $45,602
Total liabilities $101,946 $98,784 $94,833 $115,277
Stockholders' equity
Retained earnings $153,378 $153,843 $152,536 $129,381
Other stockholder equity -$10,768 -$12,527 -$8,780 -$13,135
Total stockholder equity $70,020 $68,774 $71,228 $75,149
(in millions USD) 2023 2022 2021
Current assets
Cash $21,859 $14,127 $14,487
Short term investments $1,068 $9,392 $17,121
Net receivables $14,873 $16,160 $15,283
Inventory $11,181 $12,483 $10,387
Total current assets $53,495 $55,294 $60,979
Long term investments
Property, plant & equipment $19,898 $19,803 $18,962
Goodwill & intangible assets $70,733 $93,556 $81,638
Total noncurrent assets $114,063 $132,084 $121,039
Total investments $1,068 $9,392 $17,121
Total assets $167,558 $187,378 $182,018
Current liabilities
Accounts payable $9,632 $11,703 $11,055
Deferred revenue
Short long term debt $3,451 $12,771 $3,766
Total current liabilities $46,282 $55,802 $45,226
Long term debt $25,881 $26,888 $29,985
Total noncurrent liabilities $52,502 $54,772 $62,769
Total debt $29,332 $39,659 $33,751
Total liabilities $98,784 $110,574 $107,995
Stockholders' equity
Retained earnings $153,843 $128,345 $123,060
Other stockholder equity -$12,527 -$12,967 -$13,058
Total stockholder equity $68,774 $76,804 $74,023

Income statement

(in millions USD) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Revenue
Total revenue $21,383 $13,532 $21,351 $25,530
Cost of revenue $6,511 $3,340 $6,606 $8,212
Gross profit $14,872 $10,192 $14,745 $17,318
Operating activities
Research & development $3,542 $4,246 $3,447 $3,829
Selling, general & administrative $5,257 $3,309 $5,400 $6,665
Total operating expenses $8,963 $7,669 $9,211 $10,639
Operating income $5,909 $2,523 $5,534 $6,679
Income from continuing operations
EBIT $3,869 $3,947 $27,128 $7,108
Income tax expense $459 -$121 $908 $1,618
Interest expense $155 $19 $192 $346
Net income
Net income $3,255 $4,049 $26,028 $5,144
Income (for common shares) $3,255 $4,049 $26,028 $5,144
(in millions USD) 2023 2022 2021
Revenue
Total revenue $85,159 $94,943 $93,775
Cost of revenue $26,553 $31,089 $29,855
Gross profit $58,606 $63,854 $63,920
Operating activities
Research & development $15,085 $14,603 $14,714
Selling, general & administrative $21,512 $24,765 $24,659
Total operating expenses $37,399 $40,472 $40,525
Operating income $21,207 $23,382 $23,395
Income from continuing operations
EBIT $37,661 $22,001 $22,959
Income tax expense $1,736 $3,784 $1,898
Interest expense $772 $276 $183
Net income
Net income $35,153 $17,941 $20,878
Income (for common shares) $35,153 $17,941 $20,878
(in millions USD) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Net income $3,255 $4,049 $26,028 $5,144
Operating activities
Depreciation $1,815 $1,843 $1,829 $1,934
Business acquisitions & disposals -$1,601 -$349 $121 $76
Stock-based compensation $302 $178 $296 $382
Total cash flows from operations $3,657 $7,863 $7,489 $4,182
Investing activities
Capital expenditures -$807 -$1,589 -$967 -$1,124
Investments $1,949 $632 $3,498 -$2,759
Total cash flows from investing -$464 -$1,202 $2,541 -$3,776
Financing activities
Dividends paid -$2,869 -$2,865 -$2,871 -$3,092
Sale and purchase of stock -$1,280 -$29 -$267 -$116
Net borrowings $4,602 -$1,377 -$7,233 -$7,210
Total cash flows from financing $546 -$4,655 -$11,317 -$5,991
Effect of exchange rate -$125 $125 -$168 -$97
Change in cash and equivalents $3,614 $2,131 -$1,455 -$5,682
(in millions USD) 2023 2022 2021
Net income $35,153 $17,941 $20,878
Operating activities
Depreciation $7,486 $6,970 $7,390
Business acquisitions & disposals -$112 -$17,109 $651
Stock-based compensation $1,162 $1,138 $1,135
Total cash flows from operations $22,791 $21,194 $23,410
Investing activities
Capital expenditures -$4,543 -$4,009 -$3,652
Investments $5,521 $8,976 -$5,174
Total cash flows from investing $878 -$12,371 -$8,683
Financing activities
Dividends paid -$11,770 -$11,682 -$11,032
Sale and purchase of stock -$3,960 -$4,706 -$2,420
Net borrowings -$2,953 $7,424 -$709
Total cash flows from financing -$15,825 -$8,871 -$14,047
Effect of exchange rate -$112 -$312 -$178
Change in cash and equivalents $7,732 -$360 $502

Recent institutional transactions

Quarter Shareholder Change
Shares owned
Shares
Value (in thousands USD)
2024 Q1 Whalerock Point Partners
-99.90%
33,684 $5,328,494
2024 Q1 Fmr
-19.25%
16,877,555 $2,669,860,608
2024 Q1 Amundi
+67.02%
9,989,313 $1,457,107,837
2024 Q1 Blackrock
+1.83%
189,726,768 $30,012,877,468
2024 Q1 Price T Rowe Associates Inc md/
+16.79%
21,834,359 $3,453,978
2024 Q1 Deutsche Bank Ag\
+16.98%
14,099,265 $2,230,362,731
2024 Q1 Hsbc Holdings PLC
+21.17%
9,986,772 $1,579,753,101
2024 Q1 Bank Of America Corp de/
+7.33%
23,723,391 $3,752,803,156
2024 Q1 Franklin Resources Inc
+13.62%
12,459,481 $1,970,965,324
2024 Q1 Two Sigma Advisers, L.P.
-64.01%
748,509 $118,406,639

Institutional shareholders

Shareholder Stake
Shares owned
Shares
Value (in thousands USD)
Vanguard Group Inc 9.53% 229,286,735
Blackrock 7.88% 189,726,768
State Street Corp 5.55% 133,519,781
Morgan Stanley 1.77% 42,549,943
Capital International Investors 1.20% 28,986,219
Norges Bank 1.08% 25,977,042
Wellington Management Group LL.P. 0.99% 23,746,968
Bank Of America Corp de/ 0.99% 23,723,391
Legal & General PLC 0.97% 23,261,197
Price T Rowe Associates Inc md/ 0.91% 21,834,359